Pulmatrix (NASDAQ:PULM) Stock Crosses Below Fifty Day Moving Average – Should You Sell?

Posted by Stacy Sanders on Oct 8th, 2026

Pulmatrix, Inc. (NASDAQ:PULM – Get Free Report)’s share price passed below its fifty day moving average during trading on Tuesday. The stock has a fifty day moving average of $1.54 and traded as low as $1.41. Pulmatrix shares last traded at $1.4210, with a volume of 19,471 shares.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings downgraded Pulmatrix from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, August 14th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Pulmatrix currently has a consensus rating of “Sell”.

Get Our Latest Report on PULM

Pulmatrix Trading Up 0.6%

The firm’s fifty day moving average price is $1.54 and its 200-day moving average price is $1.50. The company has a market cap of $5.47 million, a P/E ratio of -1.36 and a beta of 1.93.

Pulmatrix (NASDAQ:PULM – Get Free Report) last released its earnings results on Thursday, August 13th. The biotechnology company reported ($0.29) earnings per share for the quarter, beating the consensus estimate of ($2.00) by $1.71.

Institutional Trading of Pulmatrix

A hedge fund recently bought a new stake in Pulmatrix stock. BlackRock Inc. bought a new stake in Pulmatrix, Inc. (NASDAQ:PULM – Free Report) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 54,899 shares of the biotechnology company’s stock, valued at approximately $93,000. BlackRock Inc. owned approximately 1.50% of Pulmatrix at the end of the most recent quarter. 11.84% of the stock is currently owned by hedge funds and other institutional investors.

Pulmatrix Company Profile

(Get Free Report)

Pulmatrix, Inc (NASDAQ:PULM) is a clinical-stage biopharmaceutical company developing inhaled therapies for respiratory and other diseases. The company’s programs are based on its proprietary iSPERSE dry-powder delivery technology, which is designed to improve the delivery of drug particles to the lungs through a portable inhalation device.

Pulmatrix’s development pipeline has included PUR310, an inhaled formulation of dihydroergotamine intended for the acute treatment of migraine, as well as inhaled therapies aimed at respiratory conditions such as asthma and chronic pulmonary diseases.